Loading...
•
Dec 31, 2021
CryoPort Q4 2021 Earnings Report
Cryoport's Q4 2021 financial results were reported, showing revenue growth driven by Cryoport Systems and CRYOGENE.
Key Takeaways
Cryoport reported a 17% increase in revenue for Q4 2021, reaching $56.4 million. This growth was primarily driven by a 34% increase in organic revenue from Cryoport Systems and CRYOGENE. The company supports 602 clinical trials and 8 commercial therapies.
Q4 revenue reached $56.4 million, a 17% increase year-over-year.
Organic revenue from Cryoport Systems and CRYOGENE grew by 34%.
Cryoport supports 602 clinical trials and 8 commercial therapies globally.
Biopharma/Pharma revenue increased 18% year-over-year.
Forward Guidance
Cryoport anticipates up to nineteen additional filings, four new therapy approvals, and an additional six label or geographic expansion approvals in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...